KPMG CEO Study: CEOs Buoyed by Business Prospects, Profit

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
KPMG CEO Study: CEOs Buoyed by Business Prospects, Profit Outlook; Apprehensive Over Innovation, Regulation, Product Relevance

Three-year outlook study by KPMG finds CEOs focused on driving efficient growth; CEOs to become more acquisitive; 78 percent plan to increase hiring

NEW YORK, July 23, 2014 (GLOBE NEWSWIRE) -- Chief executives heading U.S. multinational companies are confident about the overall economy and their business prospects in the next three years and anticipate a peak profit period from 2016 to 2017. Yet, in sharp contrast to that optimism, they are also expressing a range of concerns for the same three-year outlook -- from questions about maintaining the relevance of their products and services, to their ability to innovate, to the challenges in adapting to government regulation, according to a study released today by KPMG LLP, the U.S. audit, tax and advisory firm.

"Recent years have seen a slow moving recovery coupled with fast moving innovation and global market shifts, presenting today's chief executives with an unprecedented landscape in which to set a course for growth," said John Veihmeyer, Global Chairman of KPMG and Chairman and Chief Executive Officer of KPMG in the U.S. "While confidence is growing in the fundamental strength of the economy and business prospects, CEOs face mounting concerns over managing risks and regulatory burdens and ensuring the continued relevance of their products."

In the KPMG CEO Study of 400 CEOs in the U.S., 62 percent are more confident about their growth prospects over the next three years than a year ago. In addition, 55 percent of the CEOs across several industries expect further improvement in the economy and 78 percent intend to increase head count. The CEOs also expect greater profits ahead. In looking at the next five years, 28 percent tabbed 2016 to be their greatest year for profits and 29 percent said 2017.

Despite the optimism ahead, a key KPMG study finding revealed that 72 percent of U.S. CEOs are concerned about whether their products and services will be relevant three years from now. In addition, 90 percent expressed concern about their competitors' ability to take business away from them.

Disruptive and constantly evolving technologies and changing customer expectations continue to challenge chief executives across a range of industries and sectors. The result, according to Veihmeyer, is that "a majority of businesses are transforming their operations, and leaders are focused on driving efficient growth, building their brands, and enhancing their product offerings."

When asked to identify issues that can have the most impact on their companies, the CEOs identified the regulatory environment first, followed by corporate tax reform. In fact, 34 percent of the CEOs are spending more time with regulators or government officials or considering doing so. "The pace of regulatory change is accelerating around the world," said KPMG's Veihmeyer. "CEOs will be spending increased time on the regulatory front over a number of priorities competing for attention."

Faced with many challenges, the KPMG study found CEOs less than certain about the course and speed to take their growth strategies. Study results show that CEOs are evenly split in categorizing their overall growth strategy as either aggressive or conservative.

The Need to Innovate

The KPMG study identified innovation -- with an emphasis on improving existing products over delivering new ones -- as the key differentiating factor to improve year-over-year growth and profitability.

When asked to identify barriers to innovation, 43 percent of the CEOs noted rapidly changing customer dynamics, followed by 35 percent who said budget constraints and 19 percent who said conflicting visions among executive leadership. Indicating a key challenge to successful innovation in the years ahead, only 17 percent of the CEOs said they have a fully developed process for innovation implemented across all units. However, many more of the CEOs (47 percent) from companies with revenues exceeding $10 billion said they have a formal, company-wide innovation process.

Focus on Operational Excellence, Clients

When asked to review a list of factors influencing their target operating model, the CEOs identified the need to implement greater efficiencies and cost reductions. "Driving efficient growth is a key priority and they see great possibilities leveraging new technology to enhance client services and streamline processes," said Veihmeyer. "They will also be devoting significant time to image building and increasing client touch points."

More Acquisitive

Another key strategy in the years ahead for CEOs is to become more acquisitive. Today, two-thirds of the CEOs say their current growth strategy is built around organic growth, with one-third saying it is a combination of organic and inorganic growth through acquisitions. When asked to look at their growth strategy over the next three years, 53 percent expect their priority will be organic growth, with 42 percent indicating that it will be an even split between organic and inorganic growth through acquisitions.

"The largest organizations are more acquisitive today but the results of our study indicate a coming shift to inorganic growth from businesses across size and industry in the next three years," said KPMG's Veihmeyer.

For additional information about the KPMG CEO Study, please visit here .

About KPMG LLP

KPMG LLP, the audit, tax and advisory firm ( www.kpmg.com/us ), is the U.S. member firm of KPMG International Cooperative ("KPMG International"). KPMG International's member firms have 155,000 professionals, including more than 8,600 partners, in 155 countries.

Ichiro Kawasaki KPMG LLP (201) 307-8640 Twitter: @ichiroakawasaki

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 318

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 241

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 431

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 325

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 212

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 406

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 269

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 210

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Brixton Metals Delivers Promising Drill Results in Thorn Project

Updated Category News Views 167

Brixton Metals' Latest Drill Results Brixton Metals Corporation (TSX-V: BBB, OTCQB: BBBXF) recently unveiled its second batch of drill results from the 2025 exploration season. The company operates the Thorn Project, an underexplored district known for its potential in copper-gold porphyry deposits. Highlighting Impressive Assay Results The recent drilling at the...

Continue Reading
US Labor Market Stagnation: A Closer Look at 2025 Trends

Updated Category News Views 275

November Layoffs and Hiring Trends In November, layoffs by U.S. employers reduced significantly, signaling a shift in the job market dynamics. Yet, companies are still hesitant to recruit new employees, indicating a labor market that remains restrained due to various pressures. Businesses are facing challenges such as soft demand, tariff implications, and soaring...

Continue Reading
Dollar Steady Amid Global Market Uncertainty and Yuan Weakness

Updated Category News Views 127

Asian Currency Markets React to U.S. Dollar Strength In the bustling arena of Asian currencies, the atmosphere is charged with anticipation as investors monitor the situation in China regarding potential economic stimulus measures. Meanwhile, the U.S. dollar is exhibiting remarkable strength, currently hovering near a two-and-a-half month high. This rise comes in light of...

Continue Reading
Understanding Recent Insider Trades at Omega Healthcare Invts

Updated Category News Views 75

Examining Insider Trades at Omega Healthcare Invts Recently, a notable insider trade involving Omega Healthcare Invts has drawn attention. Chief Operating Officer Daniel Booth executed a significant transaction, selling 56,725 shares as disclosed through an SEC filing. This particular sale took place on a recent date and revealed a total transaction value of $2,283,181....

Continue Reading
Exploring Future Growth in Healthcare Digital Payments Market

Updated Category News Views 150

Introduction to Digital Payments in Healthcare The transformation in the realm of healthcare is not just about treatments and services; it extends deeply into how payments are managed. The Digital Payment in Healthcare Market is evolving, with an anticipated growth in value reaching USD 61,521.8 Million by the year 2033. This incredible increase is projected to occur at a...

Continue Reading